8-K: Arvinas ARV-806 Shows Strong Preclinical KRAS G12D Data

Arvinas, Inc. announced robust preclinical data for its PROTAC KRAS G12D degrader, ARV-806, demonstrating significant tumor growth inhibition and best-in-class potential.

Summary

• Arvinas, Inc. presented preclinical data for ARV-806, a PROteolysis TArgeting Chimera (PROTAC) Kirsten rat sarcoma (KRAS) G12D degrader, at the 2025 AACR-NCI-EORTC International Conference.
• ARV-806 is designed to target both the ON and OFF forms of KRAS G12D, the most common mutation of the KRAS protein, with potential to address high unmet need in solid tumors like pancreatic, colorectal, and non-small cell lung cancer.
• In vitro, ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines, without degrading wild-type and other mutant RAS isoforms.
• ARV-806 demonstrated >25-fold greater potency in reducing cancer cell proliferation, >40-fold higher potency in degrading KRAS G12D protein, and required >10-fold lower concentrations to induce pro-apoptotic BIM expression compared to comparable clinical-stage G12D inhibitors and degraders.
• Following a single intravenous dose in a colorectal tumor xenograft model, ARV-806 degraded >90% of KRAS G12D for seven days, with parallel suppression of c-MYC and induction of BIM for five days.
• ARV-806 achieved 30% tumor volume reductions at low doses in pancreatic and colorectal cell line-derived xenograft (CDX) models and a patient-derived xenograft (PDX) model of lung cancer.
• The sustained pharmacodynamic activity supports the company's belief in intermittent clinical dosing.
• Arvinas is currently evaluating ARV-806 in a Phase 1 clinical trial (NCT07023731) for patients with KRAS G12D-mutated advanced solid tumors.
• Orally bioavailable pan-KRAS degraders have also been identified, with a tool pan-KRAS PROTAC showing robust single-agent activity and superior combination efficacy with immune checkpoint blockade (7 complete responses vs. 2 for a pan-RAS ON inhibitor).

Sentiment

Score: 9

Explanation: The preclinical data for ARV-806 is exceptionally strong, demonstrating superior potency and efficacy compared to other clinical-stage compounds in a high unmet need area. The 'best-in-class potential' claim, coupled with robust in vivo results and the advancement into Phase 1, indicates very positive sentiment.

Positives

• ARV-806 demonstrated picomolar potency in degrading KRAS G12D across multiple cancer cell lines, specifically sparing wild-type and other mutant RAS isoforms.
• The drug exhibits catalytic activity, which is crucial for overcoming upregulation, a common resistance mechanism to inhibitor treatments.
• ARV-806 showed significantly higher potency compared to other clinical-stage KRAS G12D targeting agents: >25-fold greater in reducing cancer cell proliferation, >40-fold higher in degrading KRAS G12D protein, and >10-fold lower concentrations for pro-apoptotic BIM expression.
• In vivo data showed robust and durable KRAS G12D degradation (>90% for seven days) and significant tumor volume reductions (30%) at low doses in various tumor models.
• The sustained pharmacodynamic activity suggests the potential for convenient intermittent clinical dosing.
• The company has also identified orally bioavailable pan-KRAS degraders with superior combination efficacy with immune checkpoint blockade in preclinical models.

Risks

• Actual results or events could differ materially from plans, intentions, and expectations disclosed in forward-looking statements due to various risks and uncertainties.
• There is a risk that Arvinas may not successfully conduct and complete clinical development for its product candidates, including ARV-806.
• Risks are related to drug development generally.
• Uncertainties exist regarding regulatory applications and related approval timelines.
• Arvinas's ability to protect its intellectual property portfolio is a risk.
• Reliance on third parties for aspects of development or operations poses a risk.
• There is a risk regarding Arvinas's ability to raise capital when needed.
• Whether Arvinas's cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements is a risk.

Future Outlook

Arvinas believes ARV-806 has the potential to address a high unmet need in solid tumors such as pancreatic, colorectal, and non-small cell lung cancer, and could be a best-in-class therapy for KRAS G12D mutated cancers. The sustained pharmacodynamic activity observed in preclinical models supports the potential for intermittent clinical dosing. The company also anticipates that targeted protein degradation can overcome historical limitations in addressing undruggable KRAS mutations.

Management Comments

• Angela Cacace, Ph.D., Chief Scientific Officer of Arvinas, stated: 'ARV-806's ability to eliminate both ON and OFF forms of KRAS G12D, combined with its potency and durability shown in preclinical models, supports our confidence in its clinical potential to deliver meaningful benefit for patients with KRAS G12D-mutated cancers.'

Industry Context

The announcement positions ARV-806 as a potentially significant advancement in the challenging field of KRAS-mutated cancers, which are historically difficult to treat and represent a high unmet medical need. The PROTAC mechanism of action, which harnesses the body's natural protein disposal system, offers a differentiated approach compared to traditional inhibitors, potentially overcoming resistance mechanisms like target upregulation. The identification of orally bioavailable pan-KRAS degraders further suggests a broader impact on the RAS pathway, a central driver in many cancers.

Comparison to Industry Standards

• ARV-806 demonstrated >25-fold greater potency in reducing cancer cell proliferation compared with clinical-stage KRAS G12D ON and OFF inhibitors and another clinical-stage G12D degrader.
• ARV-806 showed >40-fold higher potency in degrading KRAS G12D protein compared with a comparable clinical-stage G12D degrader.
• ARV-806 required >10-fold lower concentrations to induce pro-apoptotic BIM expression compared with clinical-stage KRAS G12D ON and OFF inhibitors and another clinical-stage G12D degrader.
• A tool pan-KRAS PROTAC demonstrated superior combination efficacy with immune checkpoint blockade (7 complete responses) compared with a pan-RAS ON inhibitor (2 complete responses).

Stakeholder Impact

• Shareholders: Positive impact due to promising preclinical data for a key pipeline asset, potentially increasing company valuation and future revenue prospects.
• Patients: Potential for a novel, highly effective treatment for KRAS G12D-mutated solid tumors, addressing a significant unmet medical need.
• Employees: Positive impact on morale and strategic direction, reinforcing the company's leadership in targeted protein degradation.
• Competitors: May face increased competitive pressure from Arvinas's differentiated PROTAC platform in the KRAS inhibition/degradation space.

Next Steps

• Continue evaluating ARV-806 in a Phase 1 clinical trial (NCT07023731) in patients with KRAS G12D-mutated advanced solid tumors.

Key Dates

Recommendation

The preclinical data for ARV-806 is highly compelling, demonstrating superior potency and efficacy against a notoriously difficult-to-treat target, KRAS G12D, compared to existing clinical-stage therapies. The 'best-in-class potential' in a high unmet medical need area, coupled with the drug's catalytic activity to overcome resistance, positions Arvinas for significant future growth. The advancement into Phase 1 clinical trials further de-risks the asset. This strong scientific validation warrants a 'strong buy' recommendation for long-term investors, despite the inherent risks of clinical development in biotechnology.

Keywords

ARV-806, KRAS G12D, PROTAC, Protein Degrader, Cancer Therapeutics, Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Oncology, Biotechnology, Clinical-stage, Preclinical Data